Mesa Laboratories (MLAB) CFO John Sakys Sells 2,756 Shares

CFO Sells Shares of Mesa Laboratories

CFO John Sakys sold 2,756 shares of Mesa Laboratories, Inc. (NasdaqGS: MLAB) on June 18, 2026, at a price of $93.23 per share. This transaction is valued at approximately $256,000. The sale comes as part of a broader trend among company insiders adjusting their holdings.

Insider Buying and Selling at Mesa Laboratories, Inc.

Sakys' sale is part of a busy day for Mesa Laboratories insiders. On the same day, Senior Vice President of Operations Brian Archbold sold 2,480 shares, while Chief Accounting Officer Crennen Lyndsey Elizabeth bought 263 shares for about $25,011. Archbold also purchased 3,324 shares earlier that day at a price of $95.10 each. These transactions suggest a mixed sentiment among the leadership at Mesa Laboratories, with some insiders opting to sell while others are buying.

Stock Performance Context

Mesa Laboratories' stock is currently trading at $93.23, which is well below its 52-week high of $132.70. The stock has seen fluctuations recently, reflecting broader market trends and investor sentiment. The current trading price is also notably lower than the 50-day moving average of $112.70. This context highlights the challenges the company faces in regaining investor confidence.

Recent Earnings

In its latest financial report, Mesa Laboratories posted revenue of approximately $249.7 million, showing a slight growth of 1% year-over-year. The earnings per share (EPS) stood at $0.85, with a net margin of 1.92%. The company is set to report its next earnings on November 5, 2026, which could provide further insights into its financial health.

Analysts Set New Price Targets

On August 14, 2026, Wells Fargo maintained an Equal-Weight rating on Mesa Laboratories with a price target of $110. This reflects a cautious outlook as analysts weigh the company's performance against market conditions. The consensus price target suggests potential upside from the current trading levels, but investor sentiment remains mixed.

What Mesa Laboratories, Inc. Does

Mesa Laboratories, Inc. develops and sells scientific instruments, focusing on life sciences tools and quality control products. The company serves various industries, including pharmaceuticals and healthcare, and is headquartered in Lakewood, Colorado. The recent insider transactions reflect the ongoing adjustments within the company as it navigates market challenges.

What's Ahead for Mesa Laboratories, Inc.

Investors will be watching for the upcoming earnings report on November 5, 2026, to gauge the company's performance. The recent insider trading activity, particularly the sales by CFO John Sakys and others, may also indicate shifting strategies within the company. As always, the 13F filings provide a look into past holdings and may not represent current positions, making the upcoming earnings report crucial for understanding Mesa Laboratories' future direction.